Introduction
CIPROFLOXACIN plasma concentrations are decreased by self-induction of microsomal enzymes after few weeks of therapy, which occasionally needs increased dosage to sustain effective therapeutic levels. It has narrow therapeutic index and complex pharmacokinetic properties, monitoring its concentration for better clinical management of patients is therefore required. The biological factors that influence the pharmacokinetics of CIPROFLOXACIN include food, age, sex etc., inturn modify time to reach maximal plasma concentration, which alters its concentration at receptor sites and influences the pharmacodynamic action. Nonethless, these factors play a significant role on drugs with narrow therapeutic rangeeither precipitates the adverse effects or masks the therapeutic action. Drug concentration maintenance plays a vital role in drugs with narrow margin of safety to overcome the therapeutic failure on one hand and to decrease the adverse effects on the other hand. Ovarian hormones alter physological functions and thereby modify absorption, distribution, metabolism and excretion of drugs which inturn modulate pharmacodynamics.The level of female hormones is phase specific and the pharmacokinetic parameters of drugs are altered by the cyclic changes in menstrual cycle. Variability in pharmacokinetics during different phases of menstrual cycle is demonstrated with Antipyrine 12 , Methaqualone 13 , Theophylline 14 , Caffeine 15 , Zidovudine 16 and Midazolam.The aim of the present research work is to study the influence of menstrual cycle (i.e., follicular phase, ovulatory phase and luteal phase) on pharmacokinetic parameters of Ciprofloxacin in patients.
II. Patients And Methods
12 female patients with their body weights ranging from 40 to 60kgs, height 140 to 160 cms and age 22 to 30 years were included in the study. The study protocol was approved by the Institutional Ethical Committee. Patients with regular menstrual cycle, not suffering from any other chronic disease not using any other drug except Ciprofloxacin were included in the study .
Patient selection
The female patients were selected from the patients who visited antibiotic department as out patients in the Warangal General Hospital, Warangal, after taking due permission from that department and written informed consent was obtained from all the patients who were willing to participate in the study. 12 female patients who complied inclusion criteria and on long term oral Ciprofloxacin therapy (not less than 2 years) with prescribed dosage regimen as per physician's prescription 500mg were selected for the study. Plasma samples were collected from each patient prior to the morning dose (0 h) and at the time points of 1, 2, 3, 4, 6, 8 & 12 hours after dosing. Plasma samples were collected after cleaning the tongue debris and mouth every time before sampling, which were stored at -80°C until further analysis. Plasma samples containing Ciprofloxacin were measured by HPLC method, on reverse phase C -18 column with a total analytical time less than 6.5 minutes 24 .
Chromatographic conditions
Mobile phase consisting of methanol: water: glacial acetic acid (67: 33: 1 v/v/v) was prepared and mixed thoroughly, degassed and used for the HPLC analysis. 1.0 ml per minute flow rate was maintained throughout the analysis. The eluent was monitored using a UV-VIS detector set at 280 nm and sensitivity was set at 0.001 a.u.f.s.
Preparation of standard graph Standard solutions
Stock solutions of 100 µg/ml each of oflaxacin and Ciprofloxacin were prepared in methanol. These solutions were further diluted with methanol to the required concentrations of each drug and stored at -4ºC. For the preparation of standard graph 0.1, 0.5, 1, 5, 10, 50 and 100 µg/ml of Ciprofloxacin in plasma was used.
Patient plasma extraction procedure
To each 100 µl of plasma sample, 20 µl of internal standard (500µg/ml Ofloxacin solution) was added and extracted with 1.7 ml of ethyl acetate, vortexed for 1 min and centrifuged at 13,000 rpm for 8 min. The supernatant was evaporated to dryness and the residue was reconstituted with 100 ul of mobile phase, vortexed for 1 min. and 20ul was injected onto HPLC. The standard solutions were also processed by similar extraction procedure. The retention times were 5.1 min. and 6.0 min. for doxycycline and Ciprofloxacin respectively. The peak area ratios obtained at different concentrations of the drug were plotted against the concentrations of the drug. The slope of this plot was calculated by least square regression analysis and was used to calculate Ciprofloxacin concentration in unknown plasma samples. Data was analysed for pharmacokinetic parameters by using WINNONLINE software.
Analysis of blank blood samples for hormones
The blank blood samples were collected from the patients before administration of the drug (0h) and analysed for concentrations of estrogen and progesterone hormones by the Chemiluminisence method..
III. Results And Discussion
The mean plasma Ciprofloxacin levels versus time in three phases of menstrual cycle were shown in Fig.1 , the plasma Ciprofloxacin levels were higher in the Follicular phase than in ovulatory and luteal phases and its levels in the ovulatory phase were lower than follicular and luteal phase. Mean concentrations of estrogen and progesterone in three phases of menstrual cycle are summerised in Table 1 . The mean levels of estrogen were 28.5 ± 16.5, 98.5 ± 110.7 and 101.26 ± 85.7 pg/ml in follicular, ovulatory and luteal phases respectively. The mean levels of progesterone were 0.6 ± 0.4, 4.5 ± 2.8 and 8.8 ± 7.2 ng/ml in follicular, ovulatory and luteal phases respectively. Mean values of various pharmacokinetic parameters of Ciprofloxacin obtained in three phases (Table 2) were compared with the values obtained in other two phases and for the calculation of percentage increase or decrease, follicular phase was treated as reference ( Table 3 ). The mean Vd/f value was increased by 53.56% in the ovulatory phase and 9.31% in luteal phase compared to follicular phase. The difference between mean Vd/f values for follicular versus ovulatory phase (P < 0.01) and luteal versus ovulatory phase (P < 0.05) was statistically significant.The mean V ss/f value was increased by 50.71% in the ovulatory phase and 6.3% in the lutealphase compared to follicular phase. The difference between mean V ss/f values for follicular versus ovulatory phase (P < 0.01) and luteal versus ovulatory phase (P < 0.01) was statistically significant.
Mean C max of Ciprofloxacin was decreased by 20% in the ovulatory phase compared to that of follicular phase and was lowest of all the three values. Similar menstrual cycle phase dependent change in Cmax was observed in case of alcohol with a lowest value at mid-cycle 25 . The highest blood alcohol concentration was found in premenstrual phase of the cycle in women and its rate of absorption varied during the menstrual cycle and was lowest at mid-cycle 26 . The mean Cmax of Paracetamol was significantly lowered in the ovulatory phase than in the follicular phase 27 due to increased first pass metabolism during ovulatory phase. Hormonal level variations and consequently physiological changes influence the pharmacokinetics of drugs by altering the properties such as gastrointestinal motility, thereby drug absorption, plasma protein levels as it alters protein binding, volume of distribution, drug metabolism and elimination. Higher levels of progesterone in luteal phase has smooth muscle relaxing effect, enhances the retention time of ingested material in small intestine, thereby it alters gastrointestinal transit and inturn drug absorption 28 . Hormone induced alterations in gastrointestinal motility are frequently reported by women during the luteal phase of the menstrual cycle 29 . Delayed gastrointestinal transit resulting from high progesterone levels potentially inhibit Lithium absorption, while the exaggerated gastrointestinal motility in the final days of the cycle due to decreased levels 30 . In concurrence with this, in the present study also progesterone levels were significantly high during luteal phase and the AUC 0-∞ of Ciprofloxacin i.e, bioavailability was decreased in luteal phase by 20% than follicular phase.
Significant changes in endogenous sex hormone concentrations occur during the menstrual cycle and pregnancy, leading to alterations in protein binding, distribution and clearance 31 . Follicular phase has higher circulating levels of α-1 acid glycoprotein (AAG), influence protein binding and changes free drug concentration, AAG concentrations are higher during the first week of the menstrual cycle than at other times 32 . It is expected that a decrease in available binding protein reduces the extent of drug protein binding, increases free drug fraction only for highly bound drugs. Alterations in protein binding affect steady-state unbound drug concentration, volume of distribution and drug half-life in a complex non-linear fashion that depends on hepatic extraction ratio and baseline parameters 33 . Specifically, highly bound drugs with high extraction ratios (eg.Tricyclic Antidepressants,Verapamil) are expected to have increased free fraction, increased volume of distribution and increased boilogical half-life (for drugs with large volume of distribution). In the present study, volume of distribution was significantly lower in follicular and luteal phases compared to ovulatory phase could be due to increased protein binding of drug, as Ciprofloxacin is highly plasma protein bound drug i.e., about 75-85%. The binding of Baclofen to neocortical membranes was varied as a function of the estrous cycle, with the lowest binding during the estrous stage in adult rat 34 . Although such menstrual cycle related drug distribution changes in humans are yet to be investigated, in this study, the mean apparent volume of distribution and volume of distribution at steady state were increased by 53.76% and 50.71% respectively during the ovulatory phase compared to follicular and luteal phases and these differences were statistically significant.
Mean AUC and C max of Ciprofloxacin were decreased and clearance was increased in luteal phase compared to follicular phase. In the previous study with Ranitidine similar changes were observed 35 . Large fluctuations in hormone concentration throughout the menstrual cycle potentially impact hepatic enzyme activity and affect the metabolism of drugs. Progesterone inhibit and induce hepatic enzyme activity [36] [37] [38] . Estrogens inhibits the metabolism of many drugs by inhibiting liver microsomal enzymes and androgens stimulate microsomal enzymes 38 . Non specific CYP substrates exhibit higher clearance and lower AUC at ovulation with prolonged clearance in the luteal phase 39 . Sex differences in drug metabolism and elimination are mainly related to steroid hormonal levels. CYP3A4, which is responsible for themetabolism of over 50% of drugs exhibit higher activity in women compared to men 40, 41 . Inter individual variability in Methyl prednisolone disposition among young women also attributed to menstrual cycle variability in CYP3A4 activity 42 . In contrast, the similarity in Alfentanil diposition on day 2, 13 and 21 suggest that hepatic cytochrome P4503A4 activity does not vary significantly with hormonal changes during the menstrual cycle 43 . Menstrual cycle changes in uterine P4503A4 content, apparently do not influence Alfentanil clearance as it metabolises Alfentanil to a lesser extent when compared with liver enzymes 44 . Similarly, Midazoram clearance was not significantly different during three major phases of the mensrual cycle, strongly suggests that hepatic CYP3A4 activity does not vary significantly with hormonal changes 45 during the menstrual cycle atleast on day 2, 13 and 21. Though non-significant, Theophylline clearance was increased and half-life was decreased in luteal phase compared to follicular phase 46 . In our study, Ciprofloxacin half-life was decreased and clearance was increased in luteal phase compared to follicular phase.
Ovulatory phase has higher clearance and smaller AUC and t1/2 of Antipyrine due to estrogenprogesterone surges in mid-cycle 12 . Similar observations in the plasma metabolism of Methaqualone were reported 46 . Higher clearance and smaller AUC 0-∞ of Ciprofloxacin in ovulatory phase compared to follicular phase was observed might be due to estrogen-progesterone surge.Plasma Vasopressin, Aldosterone concentrations and renin activity are significantly higher in the luteal phase than in the follicular phase of the menstrual cycle when plasma estrogen levels are highest 47 . Urinary kallikrein excretion is also greater in the luteal phase 48 . Another study found urinary sodium excretion to decline in the periovulatory phase. These changes have the potential to alter the distribution and excretion of medications. Both volume of distribution and clearance of Ciprofloxacin were increased in luteal phase compared to follicular phase in our study. Inter and intra-patient variation in the AUC might be due to variation in estrogen levels. A significant negative relationship was found between AUC and estradiol levels suggesting that Zidovudine glucuronidation change in relation to the menstrual cycle phase 49 . Similar results i.e. negative relationship between AUC 0-∞ of Ciprofloxacin and estradiol levels observed in ovulatory and luteal phases in our study.
Except Vd/f and V ss/f , menstrual cycle phases did not significantly affect the pharmacokinetic profile of Ciprofloxacin in terms of C max ,T max , AUC 0-∞ , AUMC 0-∞ , t 1/2 , MRT, clearance and absorption rate constant. This is in consistent with studies using Nitrazepam 50 , Alprazolam 51 and Triazolam
52
.During the follicular phase of the menstrual cycle, the levels of estrogen and progesteroneare relatively low, whereas during the mid-luteal phase, ovarian steroid hormone levelsare high 53 . Mean C max , t 1/2 and AUC of Cocaine were decreased in luteal phase
Influence of Menstrual Cycle on Pharmacokinetics of Ciprofloxacin.
DOI: 10.9790/3008-1104033035 www.iosrjournals.org 33 | Page compared to follicular phase after intravenous administration. After intranasal Cocaine, women had higher peak plasma levels during the follicular phase than during the lutealphase 54 . The C max , t 1/2 and AUC 0-∞ of Ciprofloxacin were decreased in lutealphase compared to follicular phase in the present study.
IV. Conclusion
From the above observations it can be concluded that, phase specific menstrual hormonal changes influenced Ciprofloxacin pharmacokinetics to a lesser extent and V d/f and V ss/f were significantly altered. Mean plasma concentrations of Ciprofloxacin were higher in follicular phase than in ovulatory and luteal phases. 
